Revised SPC: Solvaldi (sofosbuvir) 400 mg and 200 mg film-coated tablets
SPC has been updated with licence extension to include paediatric use in patients aged 3 to < 12 years, as a treatment of chronic hepatitis C. Also a new strength of tablet is now available (200mg), as is a new formulation (150 and 200mg coated granules).
Source:
electronic Medicines compendium